Delivery Order SPE2DB22D2007-SPE2DB25FJ4MC
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,288.86 to AmerisourceBergen Drug Corp for 100 tablets of Envarsus XR 1 mg, a tacrolimus-based immunosuppressant medication used in transplant and autoimmune disease management. Awarded on August 20, 2025, with an ultimate completion date of September 11, 2025, this firm fixed-price delivery order represents a competitively awarded transaction with no set-aside provisions. The contract will be performed at...
- The Defense Logistics Agency awarded a delivery order valued at $1,711.95 to AmerisourceBergen Drug Corp for 100 tablets of Envarsus XR 4 mg, a tacrolimus-based immunosuppressant medication commonly used in transplant patients. This is a firm fixed price delivery order with no set-aside designation, awarded on August 4, 2025, with an ultimate completion date of August 25, 2025. The order will be fulfilled from AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania. This...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency's Medical Supply Chain on July 28, 2025, for the supply of Envarsus XR 1 mg tablets (100-count packaging). This firm fixed price delivery order, valued at $2,148.10, is scheduled for completion by August 18, 2025, and represents a non-set-aside, competitively awarded contract. The delivery order is a child contract issued...
- The Defense Logistics Agency (DLA) awarded a $1,288.86 delivery order to AmerisourceBergen Drug Corp for 100 tablets of Envarsus XR 1 mg, a pharmaceutical product used in transplant immunosuppression therapy. This firm fixed-price contract, awarded on July 30, 2025, with an ultimate completion date of August 20, 2025, represents a non-competitive award issued without set-aside designation. The contract was performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $2,577.72 delivery order to AmerisourceBergen Drug Corp for 100 tablets of Envarsus XR 1 mg, a pharmaceutical product for immunosuppression. The contract, awarded on July 31, 2025, with completion targeted for August 21, 2025, utilizes firm fixed pricing with no set-aside designation, indicating competitive procurement. Performance will occur at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order represents a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,370.76 to AmerisourceBergen Drug Corp for Envarsus XR 1 mg tablets (100 count) on July 31, 2025, with completion scheduled for August 21, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The place...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Envarsus XR 1 mg tablets in quantities of 100 units. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $1,718.48 and is scheduled for completion by September 19, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child contract action under a larger vehicle, this...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Envarsus XR 4 mg tablets (100-count units) with a contract ceiling value of $5,135.85. This is a firm fixed-price delivery order with an ultimate completion date of September 10, 2025, and represents no set-aside contract, indicating it was competitively awarded. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Envarsus XR 1 mg tablets in a quantity of 100 units. This competitively awarded, non-set-aside contract carries a ceiling value of $1,718.48 with firm fixed pricing and is scheduled for completion by September 11, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Envarsus XR 1 mg tablets (30-count supply) valued at $3,106.80, with an ultimate completion date of August 15, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Envarsus XR is an extended-release formulation of tacrolimus, an immunosuppressant medication commonly used in...
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB25FJ4MCDelivery Order
The Defense Logistics Agency (DLA) awarded a $2,700.64 firm fixed price delivery order to AmerisourceBergen Drug Corp for 100 tablets of Envarsus XR 4 mg, a tacrolimus-based immunosuppressant medication used primarily in transplant patients. Awarded on August 29, 2025, with an ultimate completion date of September 22, 2025, this non-competitive delivery order represents a routine pharmaceutical supply fulfillment under the company's existing contract vehicle. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical supplier to federal medical procurement systems and holds a substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued at $999,999,999.00 through December 2026, which serves as the underlying vehicle for this delivery order. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen maintains an extensive portfolio of federal contracts with DLA and other defense health agencies, including the Defense Health Agency and U.S. Coast Guard. The company's federal procurement activities demonstrate consistent competitiveness in open awards across a diverse range of pharmaceutical products, medical devices, and healthcare commodities spanning multiple therapeutic domains. This delivery order exemplifies the company's role in supporting military healthcare logistics and the broader pharmaceutical supply chain infrastructure for the Department of Defense.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.7k | 8/29/25 |